Search Results for ""
- ACP Online (7609)
- Annals of Internal Medicine (6853)
- IM Matters (3141)
- ACP Hospitalist (2393)
- Annals of Internal Medicine: Clinical Cases (500)
- ACP Store (226)
Displaying 781 - 790 of 7609 in ACP Online
How ACP members can support current disaster recovery and aid efforts in Hawai'i
Hawaiʻi Community Foundation and Maui United Way are accepting online monetary donations to benefit Maui residents affected by fires. The Hawaiʻi Community Foundation started a Maui Strong Fund to support residents affected by the wildfires, which firefighting crews continue to battle in Lahaina, Pulehu/Kīhei and Upcountry areas. Donations can be made at www.hawaiicommunityfoundation.org/maui-strong.
How ACP members can support current disaster recovery and aid efforts
The earthquakes in Turkey and Syria are being described as the worst in that area in a century. ACP members who wish to provide support in the recovery efforts can help via these organizations. - The U.S. non-profit Bridge to Turkiye has a history of supporting cultural and educational initiatives in Turkey, and is working on providing food and water through the Turkish aid organization, Ahbap Association
Follow ACP | Blogs, Social Media, RSS
Stay up to date on the latest from the American College of Physicians and Annals of Internal Medicine by following our various media accounts. Social Media American College of Physicians
ACP 2025: The Works Package
Meet your end-of-year CME/ MOC requirements with the new ACP product, The Works! Gain immediate access to 160+ hours of video lectures & more. See details & pricing.
PPE Materials Available to ACP Members
Log in to see the special members-only offers below.
MKSAP 19 Tracker
Targeted Learning Assessment and Remediation
MKSAP 19 - Help
Questions answered for MKSAP 19, including log-in details and how to get started.
MKSAP 19 - Errata and Revisions
Review the MKSAP 19 errata and revisions.
MKSAP 19 - CME, MOC, and CPD Information for Physicians
Dates and additional details pertaining to CME and MOC submissions for MKSAP.
Displaying 781 - 790 of 6853 in Annals of Internal Medicine
These Annals of Internal Medicine results only contain recent articles.
- Visit annals.org to search all content back to 1927.
- View Annals of Internal Medicine CME by topic here.
Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19: A Target Trial Emulation Study: Annals of Internal Medicine: Vol 176, No 4
Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is uncertain. Objective: To examine the real-world effectiveness of molnupiravir and nirmatrelvir–ritonavir in hospitalized patients with COVID-19 during the Omicron outbreak. Design: Target trial emulation study. Setting: Electronic health databases in Hong Kong. Participants: The molnupiravir emulated trial included hospitalized patients with COVID-19 aged 18 years or older between 26 February and 18 July 2022 (n = 16 495). The nirmatrelvir–ritonavir emulated trial included hospitalized patients with COVID-19 aged 18 years or older between 16 March and 18 July 2022 (n = 7119). Intervention: Initiation of molnupiravir or nirmatrelvir–ritonavir within 5 days of hospitalization with COVID-19 versus no initiation of molnupiravir or nirmatrelvir–ritonavir. Measurements: Effectiveness against all-cause mortality, intensive care unit (ICU) admission, or use of ventilatory support within 28 days. Results: The use of oral antivirals in hospitalized patients with COVID-19 was associated with a lower risk for all-cause mortality (molnupiravir: hazard ratio [HR], 0.87 [95% CI, 0.81 to 0.93]; nirmatrelvir–ritonavir: HR, 0.77 [CI, 0.66 to 0.90]) but no significant risk reduction in terms of ICU admission (molnupiravir: HR, 1.02 [CI, 0.76 to 1.36]; nirmatrelvir–ritonavir: HR, 1.08 [CI, 0.58 to 2.02]) or the need for ventilatory support (molnupiravir: HR, 1.07 [CI, 0.89 to 1.30]; nirmatrelvir–ritonavir: HR, 1.03 [CI, 0.70 to 1.52]). There was no significant interaction between drug treatment and the number of COVID-19 vaccine doses received, thereby supporting the effectiveness of oral antivirals regardless of vaccination status. No significant interaction between nirmatrelvir–ritonavir treatment and age, sex, or Charlson Comorbidity Index was observed, whereas molnupiravir tended to be more effective in older people. Limitation: The outcome of ICU admission or need for ventilatory support may not capture all severe COVID-19 cases; unmeasured confounders, such as obesity and health behaviors, may exist. Conclusion: Molnupiravir and nirmatrelvir–ritonavir reduced all-cause mortality in both vaccinated and unvaccinated hospitalized patients. No significant reduction in ICU admission or the need for ventilatory support was observed. Primary Funding Source: Health and Medical Research Fund Research on COVID-19, Government of the Hong Kong Special Administrative Region; Research Grants Council, Collaborative Research Fund; and Health Bureau, Government of the Hong Kong Special Administrative Region.